ARS Pharmaceuticals, Inc. SPRY
neffy and EURneffy are trademarks of ours that we use in this Annual Report. This Annual Report also includes trademarks, trade names, and service marks that are the property of other organizations. Solely for convenience, our trademarks and trade names referred to in this Annual Report appear without the ® or symbols, but those references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights, or the right of the applicable licensor, to our trademark and trade names. The use or display of other companies' trade names or trademarks do not suggest or imply a relationship or affiliation with, or endorsement or sponsorship of us by, any other companies.
Valuation FY2025 figures against the last close
Where the revenue comes from as reported in the latest 10-K
Revenue by geography
- United States
- Rest of World
| Region | FY2025 | FY2024 |
|---|---|---|
| United States | $72.2M | $7.3M |
| Rest of World | $12.1M | $81.9M |
As the company reported it, from the “Segment Information - Schedule of Revenue by Geographic Area Based on Customers Location (Details)” note of its latest 10-K. Every figure here has been checked against the total revenue the same filing reported. Regions are the filer's own and are not mapped onto a standard list — one company's “Americas” and another's “United States” are different areas, and making them look comparable would mean making at least one of them wrong. Slices under 1% are folded into “Other”.
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | $84.3M | $89.1M | $30.0K | $1.3M | $5.5M | — | — |
| Cost of revenue | — | — | $0 | — | — | — | — |
| Gross profit | — | — | $30.0K | — | — | — | — |
| R&D | $13.2M | $19.6M | $20.3M | $18.4M | $20.3M | $24.6M | — |
| SG&A | $230.1M | $71.7M | $47.3M | $603.0K | $4.7M | $8.3M | — |
| Total operating expenses | $263.7M | $92.2M | $67.5M | $36.8M | $25.0M | $32.9M | — |
| Operating income | -$179.4M | -$3.1M | -$67.5M | -$35.5M | -$19.5M | -$32.9M | — |
| Interest expense | — | — | — | — | $106.0K | $29.0K | — |
| Pre-tax income | -$171.4M | $8.3M | -$54.4M | -$34.7M | -$20.2M | -$32.9M | — |
| Income tax | $80.0K | $288.0K | $0 | $0 | $0 | $0 | — |
| Net income | -$171.3M | $8.0M | -$54.4M | -$34.7M | -$20.2M | -$32.9M | — |
| EPS, basic | -1.74 | 0.08 | -0.57 | -0.87 | -0.70 | — | — |
| EPS, diluted | -1.74 | 0.08 | -0.57 | -0.87 | -0.70 | -11.33 | — |
| Shares, diluted (wtd. avg.) | 98.6M | 102.4M | 95.2M | 40.0M | 28.9M | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash and equivalents | $41.3M | $50.8M | $71.0M | $210.5M | $60.1M | $24.5M | $10.5M |
| Short-term investments | $203.7M | $263.2M | $157.4M | $63.9M | $0 | — | — |
| Receivables | $25.3M | $8.2M | $0 | — | — | — | — |
| Inventory | $31.4M | $10.5M | $0 | — | — | — | — |
| Total current assets | $284.9M | $334.3M | $231.7M | $277.7M | $60.7M | $390.7M | — |
| Property, plant and equipment | $2.5M | $1.1M | $574.0K | $329.0K | $72.0K | $1.6M | — |
| Other intangibles | $14.5M | $7.4M | $0 | — | — | — | — |
| Total assets | $327.7M | $351.2M | $233.2M | $281.4M | $61.4M | $394.8M | — |
| Accounts payable | $5.7M | $9.9M | $759.0K | $1.7M | $1.8M | $2.6M | — |
| Total current liabilities | $39.1M | $23.4M | $2.4M | $5.4M | $8.2M | $9.6M | — |
| Long-term debt | $96.4M | $0 | — | — | — | — | — |
| Total liabilities | $213.4M | $94.4M | $2.4M | $8.5M | $16.7M | $11.9M | — |
| Retained earnings | -$294.6M | -$123.3M | -$131.3M | -$76.9M | -$42.3M | -$96.7M | — |
| Total equity | $114.3M | $256.8M | $230.8M | $272.9M | -$31.3M | -$14.1M | -$58.8M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -$170.9M | $13.5M | -$59.3M | -$40.1M | -$17.6M | -$31.2M | — |
| Depreciation and amortisation | — | $79.0K | $73.0K | $34.0K | $213.0K | $637.0K | — |
| Stock-based compensation | $22.1M | $14.5M | $9.2M | $5.8M | $2.8M | $2.6M | — |
| Capital expenditure | $339.0K | $563.0K | $175.0K | $199.0K | $55.0K | $917.0K | — |
| Investing cash flow | $56.8M | -$106.1M | -$87.2M | -$199.0K | -$55.0K | -$917.0K | — |
| Financing cash flow | $104.6M | $72.4M | $6.9M | $190.7M | $53.2M | $408.5M | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001193125-26-191433.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Revenue | — | — | $5.5M | $1.3M | $30.0K | $89.1M | $84.3M |
| Gross profit | — | — | — | — | $30.0K | — | — |
| Net income | — | -$32.9M | -$20.2M | -$34.7M | -$54.4M | $8.0M | -$171.3M |
Recent filings and events
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Officer or director change Item 5.02
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Results announced Item 2.02
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Officer or director change Item 5.02
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
- Results announced Item 2.02
- Regulation FD disclosure Item 7.01
- Results announced Item 2.02
- Regulation FD disclosure Item 7.01
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.20T | 55.5x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $635.76B | 23.9x | 6.0% |
| ABBV | AbbVie Inc. | $504.76B | 121.0x | 8.6% |
| MRK | Merck & Co., Inc. | $358.41B | 20.0x | 1.3% |
| ABT | ABBOTT LABORATORIES | $180.63B | 27.9x | 5.7% |
| PFE | PFIZER INC | $171.16B | 22.1x | -1.6% |
| VRTX | VERTEX PHARMACEUTICALS INC / MA | $132.80B | 34.2x | 8.9% |
| BMY | BRISTOL MYERS SQUIBB CO | $125.59B | 17.8x | -0.2% |